NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $335.74 -11.66 (-3.36%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$335.51▼$352.3850-Day Range$335.74▼$457.2952-Week Range$227.21▼$459.77Volume288,125 shsAverage Volume245,615 shsMarket Capitalization$10.40 billionP/E Ratio34.22Dividend YieldN/APrice Target$423.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Medpace alerts: Email Address Medpace MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside26.0% Upside$423.00 Price TargetShort InterestHealthy3.75% of Float Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.69Based on 9 Articles This WeekInsider TradingN/AProj. Earnings Growth11.15%From $11.66 to $12.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.96 out of 5 starsMedical Sector13th out of 910 stocksCommercial Physical Research Industry1st out of 11 stocks 4.4 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.75% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 18.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedpace has received a 72.85% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Medical devices engineering", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Medpace is -0.62. Previous Next 2.6 News and Social Media Coverage News SentimentMedpace has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Medpace this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 11.15% in the coming year, from $11.66 to $12.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 34.22, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 34.22, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.85. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 13.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Medpace Stock (NASDAQ:MEDP)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More MEDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDP Stock News HeadlinesSeptember 6 at 11:33 AM | stockhouse.comMedpace Holdings, Inc. May Have Committed Securities Fraud And Stockholders Are Encouraged To Assist The Schall Law FirmSeptember 6 at 5:25 AM | americanbankingnews.comMedpace (NASDAQ:MEDP) Upgraded by StockNews.com to BuySeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.September 3, 2024 | finance.yahoo.comMedpace (MEDP) Stock Moves -1.52%: What You Should KnowAugust 29, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 28, 2024 | benzinga.comInsider Decision: Robert O Kraft Exercises Options At Medpace Hldgs For $2.78MAugust 26, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 25, 2024 | stockhouse.comAn Investigation For Securities Fraud Has Been Launched Into Medpace Holdings Inc And The Schall Law Firm Is Seeking Stockholders To ParticipateSeptember 7, 2024 | Paradigm Press (Ad) Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.August 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 380.000 putAugust 20, 2024 | ca.finance.yahoo.comMEDP Sep 2024 460.000 callAugust 20, 2024 | seekingalpha.comMedpace: Continued Business Growth With Asymmetrical Payoff OpportunityAugust 17, 2024 | finance.yahoo.comMEDP Sep 2024 420.000 put (MEDP240920P00420000)August 15, 2024 | globenewswire.comMedpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens BermanAugust 15, 2024 | finance.yahoo.comSkanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billionAugust 15, 2024 | msn.comRoad closures Saturday for Black Family Reunion Parade, Medpace 5KAugust 13, 2024 | nz.finance.yahoo.comMEDP Aug 2024 560.000 callAugust 13, 2024 | msn.comThermo Fisher Scientific Stock Sees RS Rating Jump To 81See More Headlines Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/22/2024Today9/07/2024Next Earnings (Estimated)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$423.00 High Stock Price Target$452.00 Low Stock Price Target$336.00 Potential Upside/Downside+26.0%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio34.22 Forward P/E Ratio28.79 P/E Growth1.85Net Income$282.81 million Net Margins16.74% Pretax Margin19.57% Return on Equity55.14% Return on Assets19.82% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$2.03 billion Price / Sales5.12 Cash Flow$9.52 per share Price / Cash Flow35.26 Book Value$24.63 per share Price / Book13.63Miscellaneous Outstanding Shares30,983,000Free Float24,693,000Market Cap$10.40 billion OptionableOptionable Beta1.36 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. August James Troendle M.D. (Age 68)Chairman & CEO Comp: $1.65MMr. Jesse J. Geiger BBA (Age 50)CPA, President Comp: $945.08kMr. Kevin M. Brady (Age 49)CFO & Treasurer Comp: $690.48kMs. Susan E. Burwig BSN (Age 61)MA, Executive Vice President of Operations Comp: $1.12MMr. Stephen P. Ewald J.D. (Age 55)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $914.64kBrandon EbkenChief Information OfficerMs. Lauren MorrisAssociate Director of Investors RelationsMr. Todd MeyersVice President of Business Development & MarketingJohn T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology UnitMr. Reinilde Heyrman M.D. (Age 63)Chief Medical Officer of Medical Department More ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELSyneos HealthNASDAQ:SYNHLaboratory Co. of AmericaNYSE:LHNational ResearchNASDAQ:NRCView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 3,399 shares on 9/5/2024Ownership: 0.011%Clearbridge Investments LLCBought 143,481 shares on 8/27/2024Ownership: 1.304%Cetera Investment AdvisersBought 263 shares on 8/22/2024Ownership: 0.038%Truist Financial CorpBought 648 shares on 8/21/2024Ownership: 0.012%Chase Investment Counsel CorpBought 231 shares on 8/19/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $306.53 at the beginning of 2024. Since then, MEDP shares have increased by 9.5% and is now trading at $335.74. View the best growth stocks for 2024 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) posted its quarterly earnings results on Monday, July, 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. The business's quarterly revenue was up 14.6% on a year-over-year basis. What is August Troendle's approval rating as Medpace's CEO? 268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Top institutional investors of Medpace include Riverbridge Partners LLC (1.73%), TD Asset Management Inc (1.65%), Renaissance Technologies LLC (1.43%) and Epoch Investment Partners Inc. (1.31%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD) and Bilibili (BILI). This page (NASDAQ:MEDP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.